Table 4. Prolonged survival seen in MAb-treated guinea pigs.
| MAba | Mean time to deathb (days) | No of survivors/total | Survival (%) | Student's T-test |
| 1H3 | 11.70±2.18 ( n = 5 ) | 0/5 | 0 | p = 0.018 |
| 2G4 | 11.50±1.50 ( n = 2 ) | 3/5 | 60 | N/Ac |
| 4G7 | 10.50±1.50 ( n = 2 ) | 3/5 | 60 | N/Ac |
| 5D2 | 9.40±1.02 ( n = 5 ) | 0/5 | 0 | p = 0.024 |
| 5E6 | 10.80±1.47 ( n = 5 ) | 0/5 | 0 | p = 0.009 |
| 7C9 | 9.60±0.80 ( n = 5 ) | 0/5 | 0 | p = 0.006 |
| 7G4 | 9.60±0.80 ( n = 5 ) | 0/5 | 0 | p = 0.006 |
| 10C8 | 9.40±1.20 ( n = 5 ) | 0/5 | 0 | p = 0.043 |
| PBS | 7.67±0.75 ( n = 6 ) | 0/6 | 0 | N/Ac |
a
Guinea pigs were treated i.p. with 5 mg of the MAb as shown in the table on day 1 after infection with 1000 LD50 of the GA-ZEBOV. Survival of the guinea pigs was followed. The Student's T-test compared the MAb treatment group to the PBS control.
b
Data for animals that died (number of animals in calculation).
c
N/A: not applicable.